Stock IMC IMMURON LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Immuron Limited

Equities

IMC

AU000000IMC7

Pharmaceuticals

Market Closed - Australian S.E.
Other stock markets
 02:10:44 2024-04-26 am EDT 		5-day change 1st Jan Change
0.105 AUD 0.00% Intraday chart for Immuron Limited +5.00% +36.36%
Apr. 10 Immuron Limited Provides Sales Results for the Quarter and Year to Date Ended March 2024 CI
Apr. 10 Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18% MT

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 48.54 19.59 46.35 36.36 18 17.08
Enterprise Value (EV) 1 43.82 14.47 43.16 11.33 -3.904 0.1142
P/E ratio -14.8 x -3.75 x -15.7 x -4.22 x -6.3 x -4.51 x
Yield - - - - - -
Capitalization / Revenue 26.3 x 8.2 x 18.4 x 249 x 23.5 x 9.47 x
EV / Revenue 23.8 x 6.06 x 17.1 x 77.7 x -5.1 x 0.06 x
EV / EBITDA -9.06 x -3.09 x -14.1 x -1.42 x 1.25 x -0.03 x
EV / FCF -31.5 x -33.8 x -15.7 x -6.48 x 1.68 x -0.04 x
FCF Yield -3.17% -2.96% -6.35% -15.4% 59.7% -2,491%
Price to Book 5.75 x 2.66 x 8.21 x 1.4 x 0.78 x 0.87 x
Nbr of stocks (in thousands) 142,778 163,216 178,280 227,247 227,798 227,798
Reference price 2 0.3400 0.1200 0.2600 0.1600 0.0790 0.0750
Announcement Date 9/27/18 8/30/19 8/31/20 9/30/21 9/9/22 9/28/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 1.843 2.387 2.519 0.1458 0.7652 1.805
EBITDA 1 -4.837 -4.679 -3.053 -7.954 -3.113 -3.402
EBIT 1 -4.842 -4.685 -3.072 -7.959 -3.117 -3.409
Operating Margin -262.76% -196.22% -121.97% -5,459.73% -407.4% -188.89%
Earnings before Tax (EBT) 1 -3.011 -4.633 -2.927 -8.384 -2.854 -3.787
Net income 1 -3.011 -4.633 -2.927 -8.384 -2.854 -3.787
Net margin -163.38% -194.05% -116.23% -5,751.61% -373.01% -209.81%
EPS 2 -0.0230 -0.0320 -0.0166 -0.0379 -0.0125 -0.0166
Free Cash Flow 1 -1.39 -0.4285 -2.741 -1.75 -2.33 -2.845
FCF margin -75.4% -17.95% -108.85% -1,200.28% -304.49% -157.62%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 9/27/18 8/30/19 8/31/20 9/30/21 9/9/22 9/28/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 4.73 5.12 3.19 25 21.9 17
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1.39 -0.43 -2.74 -1.75 -2.33 -2.84
ROE (net income / shareholders' equity) -40.1% -58.7% -45.1% -53.2% -11.6% -17.7%
ROA (Net income/ Total Assets) -34.5% -32.9% -26% -29.9% -7.51% -9.1%
Assets 1 8.719 14.09 11.26 28.03 38.02 41.63
Book Value Per Share 2 0.0600 0.0500 0.0300 0.1100 0.1000 0.0900
Cash Flow per Share 2 0.0300 0.0300 0.0200 0.1100 0.1000 0.0800
Capex 1 0.01 0 0 0.01 0.01 0.01
Capex / Sales 0.36% 0.09% 0.03% 4.55% 1.31% 0.43%
Announcement Date 9/27/18 8/30/19 8/31/20 9/30/21 9/9/22 9/28/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Biopharmaceuticals

1st Jan change Capi.
IMMURON LIMITED Stock Immuron Limited
+36.36% 15.57M
CSL LIMITED Stock CSL Limited
-4.66% 87.53B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 40.42B
BIOGEN INC. Stock Biogen Inc.
-19.27% 29.48B
UCB Stock UCB
+57.86% 25.43B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.49B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.3B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.1B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.75B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-8.42% 7.99B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. IMC Stock
  4. Financials Immuron Limited